Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.40 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12744589 | 0.90 | MCHR1 (0.49) | HRH3HTR2AHTR2CRORCMCHR1 | |
| SCHEMBL12744587 | 0.90 | MCHR1 (0.49) | HRH3HTR2AHTR2CRORCMCHR1 | |
| SCHEMBL25675637 | 0.82 | ACACB (0.39) | HRH3HTR2AHTR2CHSD11B1MAPK1 | |
| SCHEMBL29303928 | 0.81 | FPR1 (0.48) | HRH3HTR2AHTR2CHSD11B1MCHR1 | |
| SCHEMBL8726331 | 0.80 | ADRB1 (0.50) | HTR2AHTR2CL3MBTL1NPC1MAPT | |
| SCHEMBL15996590 | 0.80 | USP2 (0.54) | HRH3HSD11B1MAPK1L3MBTL1NPC1 | |
| SCHEMBL12666602 | 0.80 | HRH3 (0.50) | HRH3CYP3A4HSD11B1MAPK1L3MBTL1 | |
| SCHEMBL20178041 | 0.79 | HSD11B1 (0.57) | HRH3HSD11B1MAPK1L3MBTL1NPC1 | |
| SCHEMBL5539933 | 0.79 | KDM4E (0.49) | L3MBTL1MAPTLMNAL3MBTL3RORC | |
| SCHEMBL22837830 | 0.79 | HTR2A (0.43) | HTR2AHTR2CCYP3A4L3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR (CN) | 2023-05-25 | — | — | US | disclosed |
| US-9346801-B2 | Substituted 7-oxo-pyrido[2,3-d]pyrimidines and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | AMGEN INC. | 2014-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159540-A1 | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR | WEE1, WEE2, PEAK1 | HRH3 3498/4885HTR2A 4820/4885HTR2C 4534/4885 |
| US-20140249131-A1 | Substituted 7-Oxo-Pyrido[2,3-d]Pyrimidines and Methods of Use | DPYD, TYMP, TYMS | HRH3 2739/4885HTR2A 2033/4885HTR2C 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.